Avantis' Third Eye gets $12m backing:
This article was originally published in Clinica
Avantis Medical Systems is pushing forward the development and commercialisation of its leading colonoscopy device, the Third Eye Retroscope, after securing $12m in a series B round. Menlo Park, California-based VC firm Montreux Equity Partners led the financing. The Third Eye Retroscope works in tandem with a standard colonscope and is designed to detect polyps, cancers and other lesions hidden in the folds of the colon wall. A first human use study is currently in progress and a larger trial will be launched in the first quarter of 2007, says Sunnyvale, California-based Avantis.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.